Showing 4371-4380 of 5771 results for "".
- Nicox’s Licensee Bausch + Lomb Secures Approval of Vyzulta in Colombiahttps://modernod.com/news/nicoxs-licensee-bausch-lomb-secures-approval-of-vyzulta-in-colombia/2478694/Nicox announced that its partner, Bausch + Lomb, has received approval for latanoprostene bunod ophthalmic solution, 0.024% (marketed as Vyzulta In the United States) in Colombia, where it will be marketed under the brand name Cliropta. Vyzulta is currently commercialized in the United Sta
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2478693/Ocular Therapeutix announced the submission of the supplemental new drug application (sNDA) to the FDA for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use. If approved, this sNDA would include the treatment of ocular itching associated with allergic conjunctivitis as an
- Sifi Launches Well Fusion Presbyopia Correcting Systemhttps://modernod.com/news/sifi-launches-well-fusion-presbyopia-correcting-system/2478688/SIFI announces the launch of the Well Fusion system and the Mini Well Proxa IOL, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions. SIFI has develope
- Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase 3 Studies for DMEhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-and-shows-strong-durability-across-two-global-phase-3-studies-for-dme/2478687/Genentech announced positive topline results from two identically designed global phase 3 studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that
- CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidatehttps://modernod.com/news/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/2478683/CureVac NV announced that the first participant in a clinical phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a
- Nidek Launches B-scan Denoising Software With Deep Learning to Enhance OCT Retinal Image Qualityhttps://modernod.com/news/nidek-launches-b-scan-denoising-software-with-deep-learning-to-enhance-oct-retinal-image-quality/2478684/Nidek has announced the launch of the B-scan Denoising Software for the Nidek OCT series. This software converts a B-scan retinal OCT image to a high definition image by a denoising technique using deep learnin
- Kubota Vision Provides Update on Kubota Glasses—Wearable Device for Myopia Controlhttps://modernod.com/news/kubota-vision-provides-update-on-kubota-glasses-wearable-device-for-myopia-control/2478680/Kubota Vision announced that the company achieved a milestone by completing a first spectacle-style wearable prototype based on Kubota Glasses technology. Kubota Vision conducted a clinical study in early 2020 with an electronic tabletop optical projection device that embodied Kubota Glass
- Oyster Point Submits NDA to FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-submits-nda-to-fda-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478677/Oyster Point Pharma announced it has submitted a 505(b)(2) new drug application (NDA) to the FDA for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The NDA submission is supported by safety and efficacy results from the phase 3 ONSET-2, phase 2b ONSET-
- AAO: Leading Advocates for Seniors’ Timely Access to Care Legislation Applaud Senate Bill Introductionhttps://modernod.com/news/aao-leading-advocates-for-seniors-timely-access-to-care-legislation-applaud-senate-bill-introduction/2478675/The Regulatory Relief Coalition (RRC), a group of national physician specialty organizations, announced its strong support for the Improving Seniors’ Timely Access to Care Act, legislation introduced today in the U.S. Senate by Senators Sherrod Brown (D-OH) and John Thune (R-SD). The
- Wolfe Eye Clinic Performs First Surgery in Clinical Trial Evaluating an Investigational Gene Therapy for Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/wolfe-eye-clinic-performs-first-surgery-in-clinical-trial-evaluating-an-investigational-gene-therapy-for-geographic-atrophy-secondary-to-dry-amd/2478676/Wolfe Eye Clinic announced today that Jared Nielsen, MD, Retina Disease Specialist at Wolfe Eye Clinic, was recently the third surgeon in the United States and first in the Midwest to perform surgery in a clinic trial evaluating an i